Author

Erik E. Berntorp

Observed names: Berntorp, E, Berntorp, Erik, E Berntorp, E. BERNTORP, E. Berntorp, E. Berntorp, MD, Erik Berntorp, Erik E. Berntorp MD, PhD

Institution: Lund University

Observed institutions: Karolinska University Hospital, Malmö University, Lund University, Sahlgrenska University Hospital, Region Stockholm, Skåne University Hospital

ORCID: 0000-0002-2888-4931

Observed ORCID: 0000-0002-2888-4931

OpenAlex ID: A5002749259

Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B

1992 · I. M. NILSSON, E. BERNTORP, et al. · Journal of Internal Medicine · 953

Increased fetal loss in women with heritable thrombophilia

1996 · FE Preston, FR Rosendaal, et al. · The Lancet · 664

Modern haemophilia care

2012 · Erik Berntorp, Amy D Shapiro · The Lancet · 346

Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIII

1988 · Inga Marie Nilsson, Erik Berntorp, et al. · New England Journal of Medicine · 281

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

2003 · E. Berntorp, J. Astermark, et al. · Haemophilia · 273

PDF

Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A

1998 · C.A. Ludlam, B.T. Colvin, et al. · Thrombosis and Haemostasis · 212

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development

2001 · J. Astermark, E. Berntorp, et al. · Haemophilia · 208

Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients

2002 · S. ROYAL, W. SCHRAMM, et al. · Haemophilia · 192

Modern treatment of haemophilia.

1995 · E Berntorp, V Boulyjenkov, et al. · Europe PMC (PubMed Central) · 191

Pharmacokinetics of Coagulation Factors: Clinical Relevance for Patients with Haemophilia

2001 · Sven Bj??rkman, Erik Berntorp · Clinical Pharmacokinetics · 164

Prophylactic treatment for severe haemophilia: comparison of an intermediate‐dose to a high‐dose regimen

2002 · K. Fischer, J. Astermark, et al. · Haemophilia · 156

A 6‐year follow‐up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia

2004 · J. Ahnström, E. Berntorp, et al. · Haemophilia · 148

Monitoring the bioavailability of FEIBA with a thrombin generation assay

2003 · K. Váradi, C. Negrier, et al. · Journal of Thrombosis and Haemostasis · 146

PDF

Long-term prophylaxis in von Willebrand disease

2005 · Erik Berntorp, Pia Petrini · Blood Coagulation & Fibrinolysis · 122

On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome

2003 · K. Steen Carlsson, S. Höjgård, et al. · Haemophilia · 120

Social Support and the Development of Immune Function in Human Immunodeficiency Virus Infection

1995 · Tores Theorell, Vanja Blomkvist, et al. · Psychosomatic Medicine · 119

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

2001 · S. Björkman, A. D. Shapiro, et al. · Haemophilia · 116

Pharmacokinetic dosing in prophylactic treatment of hemophilia A

1993 · M. Carlsson, E. Berntorp, et al. · European Journal Of Haematology · 112

Clinical outcomes and resource utilization associated with haemophilia care in Europe

2002 · W. SCHRAMM, S. ROYAL, et al. · Haemophilia · 106

Recombinant, B-domain Deleted Factor VIII (r-VIII SQ): Pharmacokinetics and Initial Safety Aspects in Hemophilia A Patients

1997 · K Fijnvandraat, E Berntorp, et al. · Thrombosis and Haemostasis · 97

No Increased Risk of Venous Thrombosis in Women Taking Tranexamic Acid

2001 · Christina Follrud, Stefan Lethagen, et al. · Thrombosis and Haemostasis · 94

Defining extended half‐life rFVIII —A critical review of the evidence

2018 · J. Mahlangu, G. Young, et al. · Haemophilia · 92

PDF

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods

2005 · J. GOUDEMAND, I. SCHARRER, et al. · Journal of Thrombosis and Haemostasis · 88

Optimising prophylaxis in haemophilia A: The ups and downs of treatment

2021 · Erik Berntorp, Cédric Hermans, et al. · Blood Reviews · 86

PDF

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high‐titre inhibitors

2007 · J. TEITEL, E. BERNTORP, et al. · Haemophilia · 81

Works count: 244

Citation count: 8,773

H-index: 50

I10-index: 130